| Identification | Back Directory | [Name]
Metoprolol fumarate | [CAS]
80274-67-5 | [Synonyms]
Lopressor OROS
Metoprolol fumarate
Metoprolol hemifumarate
Lopressor OROS|||CGP 2175C|||CGP 2175C
1-(isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol hemifumarate
Metoprolol Fumarate (2:1)Q: What is
Metoprolol Fumarate (2:1) Q: What is the CAS Number of
Metoprolol Fumarate (2:1) Q: What is the storage condition of
Metoprolol Fumarate (2:1) Q: What are the applications of
Metoprolol Fumarate (2:1) | [Molecular Formula]
C19H29NO7 | [MOL File]
80274-67-5.mol | [Molecular Weight]
383.44 |
| Chemical Properties | Back Directory | [Melting point ]
145 - 147°C | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Uses]
Antihypertensive. | [Uses]
Metoprolol Fumarate is a β-adrenoceptor antagonist drug that is administered in an oral osmotic controlled-release system (OROS). | [Brand name]
Lopressor (Novartis). | [in vivo]
Metoprolol (2.5 mg/kg/h; infusion; 11 weeks) reduces proinflammatory cytokines and atherosclerosis in ApoE?/? Mice[1].
Metoprolol (15 mg/kg/q12h; i.g.; 5 days) shows anti-inflammation and anti-virus effects in murine model with coxsackievirus B3-induced viral myocarditis[2].
Metoprolol (2.5 mg/kg; i.v.; 3 bolus injections) significantly decreased activated caspase-9 protein expression and inhibits myocardial apoptosis in coronary microembolization (CME) rats[4]. | Animal Model: | Male ApoE?/? mice[1] | | Dosage: | 2.5?mg/kg/h | | Administration: | Via osmotic minipumps, 11 weeks | | Result: | Significantly reduced atherosclerotic plaque area in thoracic aorta, reduced serum TNFα and the chemokine CXCL1 as well as decreasing the macrophage content in the plaques. |
| Animal Model: | Balb/c mice, coxsackievirus B3 (CVB3) induced viral myocarditis (VMC) model[2] | | Dosage: | 15 mg/kg/q12h | | Administration: | Oral gavage, 5 consecutive days | | Result: | Reduced pathological scores of VMC induced by CVB3 infection, protected the myocardium against viral damage by reducing serum cTn-I levels. Decreased the levels of myocardial pro-inflammatory cytokines and increase the expression of anti-inflammatory cytokine. Significantly decreased myocardial virus titers. |
| [IC 50]
β1 adrenoceptor |
|
|